New Developments in Influenza Polymerase Inhibitors.
Jingya Li1, Yang Jin1, Yeming Wang2
1School of Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
The Journal of Infectious Diseases
|October 16, 2025
Summary
Novel influenza RNA polymerase inhibitors show promise for treating viral infections. These new antiviral agents target key viral replication enzymes, offering expanded treatment options and improved influenza control strategies.
Area of Science:
- Virology
- Drug Discovery
- Antiviral Research
Background:
- Influenza RNA polymerase is essential for viral replication.
- It is a conserved target across influenza strains, making it ideal for antiviral development.
- Existing antivirals have limitations, necessitating new therapeutic approaches.
Purpose of the Study:
- To review recent advancements in influenza RNA polymerase inhibitors.
- To discuss their mechanisms, efficacy, and resistance.
- To highlight their role in current and future influenza treatment strategies.
Main Methods:
- Literature review of preclinical and clinical studies on influenza RNA polymerase inhibitors.
- Analysis of drug mechanisms, pharmacokinetics, and efficacy data.
- Examination of emerging resistance patterns and their implications.
Main Results:
- Several novel inhibitors targeting influenza RNA polymerase subunits have been developed.
- Baloxavir, a cap-dependent endonuclease inhibitor, is approved, with others in regulatory review.
- These inhibitors demonstrate efficacy in preclinical and clinical settings.
- Emergence of resistant variants is a key consideration for long-term effectiveness.
Conclusions:
- New influenza RNA polymerase inhibitors offer expanded therapeutic options.
- They support combination antiviral therapies for enhanced influenza control.
- Continued research is vital to address viral resistance and optimize treatment strategies.
